Eisai Co (TSE:4523) 3-Year EPS without NRI Growth Rate : -51.50% (As of Dec. 2023)

View and export this data going back to 1961. Start your Free Trial

What is Eisai Co 3-Year EPS without NRI Growth Rate?

Eisai Co's EPS without NRI for the three months ended in Dec. 2023 was 円20.81.

During the past 12 months, Eisai Co's average EPS without NRI Growth Rate was 79.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was -51.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was -30.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was -7.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Eisai Co was 64.40% per year. The lowest was -51.50% per year. And the median was 1.60% per year.

Competitive Comparison of Eisai Co's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eisai Co's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eisai Co's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Eisai Co's 3-Year EPS without NRI Growth Rate falls into.

Eisai Co 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Eisai Co (TSE:4523) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Eisai Co 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Eisai Co's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Eisai Co (TSE:4523) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eisai Co Ltd (TSE:4523) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

ESAIY:USA ESALF:USA EII:Germany

Address

4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088

Website

http://www.eisai.co.jp

Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Eisai Co (TSE:4523) Headlines

No Headlines